Vivos Therapeutics Inc Revenue Growth Rates (VVOS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Vivos Therapeutics Inc   (NASDAQ: VVOS)
 

VVOS's Revenue Growth by Quarter and Year

Vivos Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VVOS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 5.15
1st Quarter March 5.06
FY 10.21

VVOSs Annual Revenue
Vivos Therapeutics Inc 's Revenue in the fiscal year 2025 $ 16.54 millions
Vivos Therapeutics Inc 's Revenue in the fiscal year 2024 $ 15.02 millions
Vivos Therapeutics Inc 's Revenue in the fiscal year 2023 $ 13.27 millions
Vivos Therapeutics Inc 's Revenue in the fiscal year 2022 $ 16.02 millions
Vivos Therapeutics Inc 's Revenue in the fiscal year 2021 $ 16.89 millions




VVOS Revenue second quarter 2026 Y/Y Growth Comment
Vivos Therapeutics Inc achieved in the second quarter 2026, above Company average Revenue rise of 65.69% year on year, to $ 5.15 millions.

Looking into second quarter 2026 results within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue growth. While Vivos Therapeutics Inc ' s Revenue jump of 65.69% ranks overall at the positon no. 374 in the second quarter 2026.


VVOS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -2.16 % 49.12 % -13.42 %
3rd Quarter September - 78.38 % 14.83 % -31.76 %
2nd Quarter June 65.69 % -14.79 % 17.74 % -25.84 %
1st Quarter March 101.59 % -14.63 % -23.83 % 6.04 %
FY   - 10.19 % 13.1 % -

Financial Statements
Vivos Therapeutics Inc 's second quarter 2026 Revenue $ 5.15 millions VVOS's Income Statement
Vivos Therapeutics Inc 's second quarter 2025 Revenue $ 3.11 millions Quarterly VVOS's Income Statement


VVOS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -15.99 % 53.15 % 17.93 %
3rd Quarter September - 91 % -8.77 % -6.45 %
2nd Quarter June 1.84 % 23.9 % 24.15 % -19.69 %
1st Quarter March 1.4 % -50.78 % -14.04 % -2.28 %
FY (Year on Year)   - 10.19 % 13.1 % -


Back to VVOS Growth rate Comparisons >> Back to VVOS Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #100
Overall #374

Revenue Y/Y Growth Statistics
High Average Low
101.63 % 13.86 % -31.75 %
(Sep 30 2023)   (Mar 31 2024)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #100
Overall #374
Revenue Y/Y Growth Statistics
High Average Low
101.63 % 13.86 % -31.75 %
(Sep 30 2023)   (Mar 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Vivos Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
90.9 % 4.94 % -50.77 %
(Sep 30 2025)  


VVOS's II. Quarter Q/Q Revenue Comment
Vivos Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue growth of 1.84% quarter on quarter, to $ 5.15 millions.

Within Medical Equipment & Supplies industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Vivos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1496.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #63
Healthcare Sector #207
Overall #1496
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #63
Healthcare Sector #207
Overall #1496
Revenue Q/Q Growth Statistics
High Average Low
90.9 % 4.94 % -50.77 %
(Sep 30 2025)  


VVOS's II. Quarter Q/Q Revenue Comment
Vivos Therapeutics Inc achieved in the II. Quarter 2026 below company average Revenue growth of 1.84% quarter on quarter, to $ 5.15 millions.

Within Medical Equipment & Supplies industry 62 other companies have achieved higher Revenue quarter on quarter growth. While Vivos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1496.


Vivos Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 21.14 $ 19.09 $ 16.54 $ 16.65 $ 14.05
Y / Y Revenue Growth (TTM) 50.43 % 30.85 % 10.14 % 24.84 % 8.88 %
Year on Year Revenue Growth Overall Ranking # 1527 # 721 # 971 # 1916 # 2768
Seqeuential Revenue Change (TTM) 10.7 % 15.42 % -0.67 % 18.53 % -3.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 2761 # 2354 # 1004 # 1430 # 1567


Cumulative Revenue growth Comment
Although Vivos Therapeutics Inc 's Annual Revenue growth year on year were below company's average 82.35% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 50.43% year on year, from 30.85% in Mar 31 2026.

In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 721 to 1527.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 142
Healthcare Sector # 252
Overall # 1527

Revenue TTM Y/Y Growth Statistics
High Average Low
355.35 %
 82.35 %
-23.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 142
Sector # 394
S&P 500 # 2761
Cumulative Revenue growth Comment
Although Vivos Therapeutics Inc 's Annual Revenue growth year on year were below company's average 82.35% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 50.43% year on year, from 30.85% in Mar 31 2026.

In the Healthcare sector 251 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 721 to 1527.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 142
Healthcare Sector # 252
Overall # 1527

Revenue TTM Y/Y Growth Statistics
High Average Low
355.35 %
82.35 %
-23.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 142
Sector # 394
S&P 500 # 2761




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VVOS's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions


About Vivos Therapeutics Inc Revenue Growth Rates (VVOS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Vivos Therapeutics Inc (CIK 1716166).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-26-038336
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Vivos Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.